Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers discover new way to kill pediatric brain tumors

10.02.2010
Researchers at Washington University School of Medicine in St. Louis have shown once again that "ready, fire, aim," nonsensical though it may sound, can be an essential approach to research.

The scientists robotically "fired" 2,000 compounds into culture plates containing tumor cells to see if the compounds had any effect. When the robotic screener found one substance had scored a hit by inhibiting growth of the tumor cells in its plate, researchers analyzed what that compound acted against. Follow-up studies showed that the drug slowed tumor growth in mice by inhibiting the function of a protein called STAT3.

As a result, researchers now have a previously unrecognized target, STAT3, at which they can "aim" new drugs for the treatment of cancer in neurofibromatosis-1 (NF1), a genetic condition that causes increased risk of benign and malignant brain tumors.

"We were excited to find that the slowed tumor growth we observed following treatment resulted from increased tumor cell death — an effect we hadn't seen before when we blocked other NF1 growth control molecules," says senior author David H. Gutmann, M.D., Ph.D., the Donald O. Schnuck Family Professor of Neurology. "Now we can identify the genes that STAT3 influences to fine-tune our treatments and ensure that we kill cancer cells with minimal harm to normal cells."

Gutmann is director of the Neurofibromatosis Center at Washington University, a national referral center for patients with all forms of neurofibromatosis. The center is active both in clinical trials and in basic research to help develop innovative new approaches for treating patients with NF. Gutmann is also co-director of the neuro-oncology program at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital.

Gutmann collaborated on this project with David Piwnica-Worms, M.D., Ph.D., professor of radiology and of developmental biology and director of the Molecular Imaging Center at Washington University. The results appear this month in the journal Cancer Research.

Cucurbitacin-I, the compound that led scientists to STAT3, is a plant steroid. It belongs to a family of bitter-tasting compounds previously identified as inhibitors of STAT3. Gutmann says cucurbitacin-I is likely too toxic to be suitable for use in clinical trials at this time.

After the successful robotic test of cucurbitacin-I, researchers showed that STAT3, which turns on and off the activity of a number of genes, is unusually active in NF1 tumor cells. Further investigation revealed that STAT3 activity is regulated by another gene very familiar to Gutmann: the mammalian target of rapamycin (mTOR).

Gutmann's laboratory linked mTOR and the processes it controls to NF1 years ago. The new connection between STAT3 and the mTOR pathway makes STAT3 the last link in a chain of molecules that take growth-promoting signals from the cell membrane to the nucleus. Gutmann says he is encouraged by the possibility that scientists might be able to decipher the genetic program controlled by STAT3 in order to develop more refined treatments for tumors in patients with NF1.

"We went in with a 'we don't know enough' approach, let's try 'ready, fire, aim,' and it paid off," he says.

Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, Reilly KM, Piwnica-Worms DR, Gutmann DH. Neurofibromin controls cell growth by regulating signal transducer and activator of transcription 3 activity in vitro and in vivo. Cancer Research, Feb. 15, 2010.

Funding from the Department of Defense, the National Institutes of Health and the Siteman Cancer Center supported this research.

Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked third in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Michael C. Purdy | EurekAlert!
Further information:
http://www.wustl.edu

More articles from Life Sciences:

nachricht Breakthrough in designing a better Salmonella vaccine
25.09.2018 | University of California - Davis

nachricht Proof of Concept: Gene therapy for mitochondrial diseases
25.09.2018 | Max-Planck-Institut für Biologie des Alterns

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Hygiene at your fingertips with the new CleanHand Network

The Fraunhofer FEP has been involved in developing processes and equipment for cleaning, sterilization, and surface modification for decades. The CleanHand Network for development of systems and technologies to clean surfaces, materials, and objects was established in May 2018 to bundle the expertise of many partnering organizations. As a partner in the CleanHand Network, Fraunhofer FEP will present the Network and current research topics of the Institute in the field of hygiene and cleaning at the parts2clean trade fair, October 23-25, 2018 in Stuttgart, at the booth of the Fraunhofer Cleaning Technology Alliance (Hall 5, Booth C31).

Test reports and studies on the cleanliness of European motorway rest areas, hotel beds, and outdoor pools increasingly appear in the press, especially during...

Im Focus: Scientists present new observations to understand the phase transition in quantum chromodynamics

The building blocks of matter in our universe were formed in the first 10 microseconds of its existence, according to the currently accepted scientific picture. After the Big Bang about 13.7 billion years ago, matter consisted mainly of quarks and gluons, two types of elementary particles whose interactions are governed by quantum chromodynamics (QCD), the theory of strong interaction. In the early universe, these particles moved (nearly) freely in a quark-gluon plasma.

This is a joint press release of University Muenster and Heidelberg as well as the GSI Helmholtzzentrum für Schwerionenforschung in Darmstadt.

Then, in a phase transition, they combined and formed hadrons, among them the building blocks of atomic nuclei, protons and neutrons. In the current issue of...

Im Focus: Patented nanostructure for solar cells: Rough optics, smooth surface

Thin-film solar cells made of crystalline silicon are inexpensive and achieve efficiencies of a good 14 percent. However, they could do even better if their shiny surfaces reflected less light. A team led by Prof. Christiane Becker from the Helmholtz-Zentrum Berlin (HZB) has now patented a sophisticated new solution to this problem.

"It is not enough simply to bring more light into the cell," says Christiane Becker. Such surface structures can even ultimately reduce the efficiency by...

Im Focus: New soft coral species discovered in Panama

A study in the journal Bulletin of Marine Science describes a new, blood-red species of octocoral found in Panama. The species in the genus Thesea was discovered in the threatened low-light reef environment on Hannibal Bank, 60 kilometers off mainland Pacific Panama, by researchers at the Smithsonian Tropical Research Institute in Panama (STRI) and the Centro de Investigación en Ciencias del Mar y Limnología (CIMAR) at the University of Costa Rica.

Scientists established the new species, Thesea dalioi, by comparing its physical traits, such as branch thickness and the bright red colony color, with the...

Im Focus: New devices based on rust could reduce excess heat in computers

Physicists explore long-distance information transmission in antiferromagnetic iron oxide

Scientists have succeeded in observing the first long-distance transfer of information in a magnetic group of materials known as antiferromagnets.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

"Boston calling": TU Berlin and the Weizenbaum Institute organize a conference in USA

21.09.2018 | Event News

One of the world’s most prominent strategic forums for global health held in Berlin in October 2018

03.09.2018 | Event News

4th Intelligent Materials - European Symposium on Intelligent Materials

27.08.2018 | Event News

 
Latest News

Establishing metastasis

25.09.2018 | Health and Medicine

Artificial intelligence to improve drug combination design & personalized medicine

25.09.2018 | Health and Medicine

Small modulator for big data

25.09.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>